Market Pulse Archives

March 30, 2020, 7:39 a.m. EDT

J&J has a COVID-19 vaccine candidate, Phase 1 trials to start in September

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -0.46% gained 5% in premarket trading on Monday after the company said it had identified a lead candidate in its efforts to develop a COVID-19 vaccine. J&J said Monday it plans to begin Phase 1 clinical trials of the vaccine candidate in humans in September, and the investigational vaccine may be ready for emergency use authorization from the Food and Drug Administration by early 2021. The company is also scaling up its vaccine manufacturing capabilities in the U.S. and abroad as part of its commitment to bring "an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use." A number of companies including Moderna Inc. /zigman2/quotes/205619834/composite MRNA -0.72% are developing vaccines that would prevent infections from the novel coronavirus that has sickened more than half a million people worldwide. Year-to-date, J&J's stock is down 15%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.11% has tumbled 21%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 146.67
-0.69 -0.46%
Volume: 1.58M
Aug. 4, 2020 12:37p
P/E Ratio
25.77
Dividend Yield
2.76%
Market Cap
$387.95 billion
Rev. per Employee
$603,509
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 77.42
-0.56 -0.72%
Volume: 5.76M
Aug. 4, 2020 12:38p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$30.32 billion
Rev. per Employee
$177,721
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,298.29
+3.68 +0.11%
Volume: 1.18B
Aug. 4, 2020 12:38p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.